Stocktwits on MSN
Johnson & Johnson’s Newly Acquired Antipsychotic Drug Approved By FDA For Major Depressive Disorder
The new approval is the first for the drug under JNJ leadership. ・The drug is also approved for the treatment of bipolar I ...
Fierce Pharma
J&J's Caplyta supersizes its reach with FDA nod as add-on treatment for major depressive disorder
Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...
J&J’s Caplyta wins MDD approval to extend revenue horizon
Caplyta (lumateperone) has scored a label extension into the depression setting, underscoring the belief Johnson & Johnson (J ...
pharmaphorum
J&J adds first new indication for Caplyta since takeover
The US regulator has cleared Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major ...
US FDA expands use of J&J's Caplyta as add-on depression drug
The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug Caplyta as an add-on ...